Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis.

Journal of Lipid and Atherosclerosis
Won Kyeong JeonKyung Woo Park

Abstract

Recent studies have raised concern about the cardiovascular safety of dipeptidyl peptidase-4 (DPP4) inhibitors. We performed a systematic review through meta-analysis to compare cardiovascular outcomes of sulfonylurea (SU) versus DPP4 inhibitors when used in combination with metformin. After searching for trials using combination therapy of metformin with DPP4 inhibitor or SU in PubMed, Cochrane Library, and Embase, one prospective observation study and 15 randomized controlled studies were selected. Regarding the primary analysis endpoint, there were no significant differences in the risk of all-cause mortality between SU and DPP4 inhibitors as an add-on therapy to metformin (random-effect relative risk [RR], 1.14; 95% confidence interval [CI], 0.98-1.33; p=0.811; I2=0%). Cardiovascular death was also similar between the two drug classes in the five studies which reported outcomes (random-effect RR, 1.03; 95% CI, 0.83-1.27; p=0.517; I2=0%). Furthermore, there were no significant differences in major adverse cardiac events (MACE), coronary heart disease, myocardial infarction, ischemic stroke and heart failure. However, there were less hypoglycemic events and weight gain in the DPP4 inhibitor group as compared with the SU group...Continue Reading

References

Aug 19, 2004·Diabetes Research and Clinical Practice·Roderick E Warren
Aug 1, 2006·Diabetes Research and Clinical Practice·Juliana C N ChanPaul Zimmet
Aug 26, 2009·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J E Foley, S Sreenan
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association
May 12, 2010·International Journal of Clinical Practice·T SeckUNKNOWN Sitagliptin Study 024 Group
Jan 29, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Juan C Arjona FerreiraBarry J Goldstein
Apr 19, 2013·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
Aug 8, 2013·Expert Opinion on Pharmacotherapy·Carolyn F Deacon, Jens J Holst
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Feb 11, 2014·Diabetes Research and Clinical Practice
May 6, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jul 21, 2016·JAMA : the Journal of the American Medical Association·Suetonia C PalmerGiovanni F M Strippoli
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators
Jul 6, 2019·Frontiers in Endocrinology·Baptist Gallwitz
Sep 20, 2019·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CAROLINA Investigators

❮ Previous
Next ❯

Software Mentioned

SE
STATA

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.